Skip to content

Half effective dose of sufentanil in combination with different doses of remimazolam benzenesulfonate for the induction of general anesthesia to suppress the response to tracheal intubation

Half effective dose of sufentanil in combination with different doses of remimazolam benzenesulfonate for the induction of general anesthesia to suppress the response to tracheal intubation

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075949
Enrollment
Unknown
Registered
2023-09-20
Start date
2023-10-01
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with general anesthesia

Interventions

Remimazolam dose 0.25 mg/kg:Anesthesia was induced with remimazolam 0.25mg/kg, and the 50% effective dose of sufentanil was determined.
Remimazolam dose 0.35 mg/kg:Anesthesia was induced with remimazolam 0.25mg/kg, and the 50% effective dose of sufentanil was determined.

Sponsors

Department of Anesthesiology, Nanchong City Hospital, Second Clinical Medical College, North Sichuan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ? Patients undergoing elective general anesthesia surgery, regardless of gender, aged 18-65 years; ? BMI 19-28kg/m2; ?ASA ?-?; All participants agreed to participate in the study and signed

Exclusion criteria

Exclusion criteria: (1) Acute heart failure, unstable angina, or myocardial infarction within 6 months. ? Enter the room to measure the baseline values: systolic blood pressure > 160mmHg or diastolic blood pressure > 100mmHg, heart rate 100bpm. Acute respiratory infection, acute exacerbation of COPD, poorly controlled asthma ? End-stage renal failure and hepatic decompensation ? Mental disorders including: schizophrenia, depression, cognitive dysfunction, etc. ?Allergy to the study drug (vii) History of benzodiazepine medication in the last three months. ? Pregnant and lactating women. ? Patients with anticipated difficult airways.

Design outcomes

Primary

MeasureTime frame
median effective dose;

Secondary

MeasureTime frame
Vital signs during intubation;Time to complete endotracheal intubation;Number of adverse reactions;

Countries

China

Contacts

Public ContactLi Linji

Department of Anesthesiology, Nanchong City Hospital, Second Clinical Medical College, North Sichuan Medical College

llj-stephen@163.com+86 155 8300 9555

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026